Trial Profile

A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute-Pancreas (Algenpantucel-L) Immunotherapy in Subjects with Surgically Resected Pancreatic Cancer

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Feb 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Algenpantucel-L (Primary) ; Fluorouracil; Gemcitabine
Indications Pancreatic cancer
Focus Registrational; Therapeutic Use
Acronyms IMPRESS
Sponsors NewLink Genetics Corporation

Most Recent Events

20 Sep 2016 Status changed from active, no longer recruiting to completed.
09 May 2016 Results published in a NewLink Genetics Corporation media release.
09 May 2016 Primary endpoint (Overall survival) has not been met, according to a NewLink Genetics Corporation media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com